Thus, restoring TFAP4 expression in c-MYC driven blood cancers, might ameliorate disease progression, not by killing the tumour cells, but by inducing normal differentiation of the self-renewing pre-B lymphoma cell pool into less proliferative immature/mature B cells, albeit only if these cells are dependent on sustained absence of TFAP4 for lymphoma maintenance and not only for lymphoma development. The gene discussed is MYC; the disease is lymphoma.